Details for New Drug Application (NDA): 208424
✉ Email this page to a colleague
NDA 208424 describes GONITRO, which is a drug marketed by Pohl Boskamp and is included in one NDA. There is one patent protecting this drug. Additional details are available on the GONITRO profile page.
The generic ingredient in GONITRO is nitroglycerin. There are thirty-six drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the nitroglycerin profile page.
The generic ingredient in GONITRO is nitroglycerin. There are thirty-six drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the nitroglycerin profile page.
Summary for 208424
| Tradename: | GONITRO |
| Applicant: | Pohl Boskamp |
| Ingredient: | nitroglycerin |
| Patents: | 1 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 208424
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;SUBLINGUAL | Strength | 0.4MG/PACKET | ||||
| Approval Date: | Jun 8, 2016 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Try a Trial | Patent Expiration: | Mar 11, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
